Haleon (HLN) EBITDA Margin (2021 - 2025)

Haleon's (HLN) quarterly EBITDA Margin came in at 21.95% in Q4 2025, up 8.63% on a QoQ basis from 20.21% in Q4 2023.

Haleon (HLN) EBITDA Margin (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of EBITDA Margin data on file, last reported at 21.95% in Q4 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 21.95% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 20.62% (changed N/A YoY) and the FY2025 annual result came in at 21.87%, down 310.0% from the prior year.
EBITDA Margin rose to 21.95% in Q4 2025, from 20.21% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 55.92% in Q4 2022 to a low of 17.61% in Q4 2021.
A 4-year average of 25.89% and a median of 20.6% in 2023 frame the typical range for EBITDA Margin.
Annual changes were most pronounced in 2022 — EBITDA Margin jumped 3831 bps — and 2023, when it tumbled 3571 bps.
Tracing HLN's EBITDA Margin over 4 years: stood at 17.61% in 2021, then soared by 218 bps to 55.92% in 2022, then sank by 64 bps to 20.21% in 2023, then advanced by 9 bps to 21.95% in 2025.
The last three EBITDA Margin figures came in at 21.95% (Q4 2025), 20.21% (Q4 2023), and 18.68% (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-5.58%
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	42.23%
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn	3.70%

Download Data